WPD has 9 novel drug candidates with 4 that are in clinical development stage and 5 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.